Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Biotech
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
From dual-payload ADCs to bispecifics and radioligands, drugmakers are hunting for answers either after Enhertu progression or to replace it.
Angus Liu
Oct 28, 2026 9:00am
BioNTech sees limited ADC benefit as ph. 3 shows modest efficacy
Oct 26, 2026 8:39am
SimBioSys nabs FDA OK for AI breast cancer recurrence tool
Oct 16, 2026 9:00am
Fierce Pharma
FDA's surprise approval of AZ's oral SERD sets new paradigm
Sep 8, 2026 10:35am
Guardant wins FDA nod for test guiding AstraZeneca’s Etcamah
Sep 7, 2026 2:08am
Fierce Pharma
Celcuity set to be Big Pharma 'strategic target' after approval
Jul 14, 2026 4:56pm